{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464193974
| drug_name = 
| IUPAC_name = (2''S'')-2-[(4-<nowiki/>{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid
| image = Methotrexate skeletal.svg
| width = 300
| image2 = Methotrexate ball-and-stick model.png
| width2 = 300

<!--Clinical data-->
| pronounce = {{IPAc-en|audio=En-us-Methotrexate.ogg|ˌ|m|ɛ|θ|ə|ˈ|t|r|ɛ|k|ˌ|s|eɪ|t|,_|ˌ|m|iː|-|,_|-|θ|oʊ|-}}{{refn|{{cite web |url=https://www.oxforddictionaries.com/definition/english/methotrexate |title=methotrexate - definition of methotrexate in English from the Oxford dictionary |publisher=[[OxfordDictionaries.com|OxfordDictionaries.com]] |access-date=2016-01-20 |archive-date=2015-12-04 |archive-url=https://web.archive.org/web/20151204122550/http://www.oxforddictionaries.com/definition/english/methotrexate |dead-url=no }}}}{{refn|{{MerriamWebsterDictionary|methotrexate}}}}
| tradename = Trexall, Rheumatrex, others
| Drugs.com = {{drugs.com|monograph|methotrexate}}
| MedlinePlus = a682019
| licence_US = Methotrexate
| pregnancy_AU = D
| pregnancy_US = X
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[Wiktionary:oral|By mouth]], [[intravenous|IV]], [[intramuscular|IM]], [[Subcutaneous_injection|SC]], [[intrathecal|intrathecal]]

<!--Pharmacokinetic data-->
| bioavailability = 60% at lower doses, less at higher doses.<ref name = MSR>{{cite web|title=Trexall, Rheumatrex (methotrexate) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=12 April 2014|url=http://reference.medscape.com/drug/trexall-methotrexate-343201#showall|archive-date=2014-02-08|archive-url=https://web.archive.org/web/20140208210608/http://reference.medscape.com/drug/trexall-methotrexate-343201#showall|dead-url=no}}</ref>
| protein_bound = 35–50% (parent drug),<ref name = MSR/> 91–93% (7-hydroxymethotrexate)<ref name = drugs94>{{cite journal|last=Bannwarth|first=B|author2=Labat, L |author3=Moride, Y |author4= Schaeverbeke, T |title=Methotrexate in rheumatoid arthritis. An update. |journal=Drugs |date=January 1994 |volume=47 |issue=1 |pages=25–50 |doi=10.2165/00003495-199447010-00003 |pmid=7510620}}</ref>
| metabolism = [[Hepatic|Hepatic]] and intracellular<ref name = MSR/>
| elimination_half-life = 3–10 hours (lower doses), 8–15 hours (higher doses)<ref name = MSR/>
| excretion = Urine (80–100%), faeces (small amounts)<ref name = MSR/><ref name = drugs94/>

<!--Identifiers-->
| IUPHAR_ligand = 4815
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59-05-2
| ATC_prefix = L01
| ATC_suffix = BA01
| ATC_supplemental = {{ATC|L04|AX03}}
| PubChem = 126941
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00563
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 112728
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YL5FZ2Y5U1
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00142
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 44185
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 34259
| PDB_ligand = MTX
<!--Chemical data-->
| C=20 | H=22 | N=8 | O=5
| molecular_weight = 454.44 g/mol
| smiles = O=C([C@H](CCC(O)=O)NC(C1=CC=C(N(CC2=CN=C(N=C(N)N=C3N)C3=N2)C)C=C1)=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FBOZXECLQNJBKD-ZDUSSCGKSA-N
}}

<!-- Definition and medical uses -->
'''氨甲蝶呤'''（{{lang-en|Methotrexate}}，又称'''甲氨喋呤'''、'''甲氨蝶呤'''、'''氨甲喋呤'''；在台灣，學名為'''胺基甲基葉酸'''，商品名為'''滅殺除癌錠'''及'''治善錠'''）是一種[[化療藥物|化療藥物]]和[[免疫抑制劑|免疫抑制劑]]<ref name=AHFS2016>{{cite web|title=Methotrexate|url=https://www.drugs.com/monograph/methotrexate.html|work=The American Society of Health-System Pharmacists|accessdate=22 Aug 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161008130258/https://www.drugs.com/monograph/methotrexate.html|archivedate=2016-10-08|df=}}</ref>，用來治療[[癌症|癌症]]、[[自體免疫疾病|自體免疫疾病]]、[[子宮外孕|子宮外孕]]和進行藥物流產<ref name=AHFS2016/> 。可治療的癌症類型包含[[乳癌|乳癌]]、[[白血病|白血病]]、[[肺癌|肺癌]]、[[淋巴癌|淋巴癌]]和{{le|骨肉瘤|Osteosarcoma}}<ref name=AHFS2016/> 。可治療的自體免疫疾病包含[[銀屑病|銀屑病]]、[[類風溼性關節炎|類風溼性關節炎]]和[[克隆氏症|克隆氏症]]<ref name=AHFS2016/> 。使用方式為口服或注射<ref name=AHFS2016/> 。

<!-- Side effects and mechanism -->
本藥物為[[葉酸|葉酸]]拮抗劑，與葉酸差異僅在N<sub>10</sub>上的NH上的氫改為甲基(CH<sub>3</sub>)，以及環上C<sub>4</sub>酮基改為氨基(NH<sub>2</sub>)，故可與葉酸競爭同一酵素，是[[抗代謝療法藥物|抗代謝療法藥物]]可阻止[[尿嘧啶|尿嘧啶]]透過葉酸轉移一個甲基形成[[胸腺嘧啶|胸腺嘧啶]]，即是[[抗腫瘤藥|抗腫瘤藥]]，或預防移植體對宿主[[排异反应|排斥反应]]之葯物。常見的副作用包含噁心、疲倦、發燒、增加感染風險、[[白血球計數降低|白血球減少症]]、[[口腔炎|口腔炎]]<ref name=AHFS2016/>。其他副作用包含[[肝病|肝病]]、[[肺病|肺病]]、[[淋巴瘤|淋巴瘤]]和嚴重皮疹<ref name=AHFS2016/>。長期使用本藥者應定時檢查副作用<ref name=AHFS2016/>；而在[[母乳哺育|母乳哺育]]時服用不安全<ref name=AHFS2016/>；至於對[[腎臟病|腎臟病]]患者可能須減少劑量<ref name=AHFS2016/>。本藥的作用原理為阻止身體利用[[葉酸|葉酸]]。

<!-- History society and culture -->
本藥最初是由印度生物化學家{{Link-en|耶拉普拉伽达·苏巴拉奥|Yellapragada Subbarao}}在1947年合成出來，他的大部分職業生涯都在美國。之後由美國兒科醫生西德尼·法伯 (Sidney Farber)開始使用於癌症的臨床治療，因為其毒性較當時的其他藥物低<ref>{{cite book|last1=Sneader|first1=Walter|title=Drug Discovery: A History|date=2005|publisher=John Wiley & Sons|isbn=9780470015520|page=251|url=https://books.google.com/books?id=jglFsz5EJR8C&pg=PA251|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170216080949/https://books.google.com/books?id=jglFsz5EJR8C&pg=PA251|archivedate=2017-02-16|df=}}</ref>。1950年代，本藥開始取代毒性更強的抗葉酸藥物{{Link-en|氨基蝶呤|Aminopterin}}，於1956年時已用來作為[[轉移性癌症|轉移性癌症]]的第一線治療藥物<ref>{{cite news|title=Today’s anti-cancer tools are ever better wielded|url=https://www.economist.com/news/technology-quarterly/21728780-they-are-sharper-too-todays-anti-cancer-tools-are-ever-better-wielded|accessdate=16 September 2017|work=[[The_Economist|The Economist]]|date=14 September 2017|archive-date=2018-05-15|archive-url=https://web.archive.org/web/20180515011418/https://www.economist.com/news/technology-quarterly/21728780-they-are-sharper-too-todays-anti-cancer-tools-are-ever-better-wielded|dead-url=no}}</ref>。本藥現已列載於[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]上，代表其是醫療系統所需最有效且安全的藥物之一<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref>，現今市面上也有其他的[[學名藥|學名藥]]<ref name=AHFS2016/> 。2014年[[開發中國家|開發中國家]]中一日所需口服形式氨甲蝶呤批發價介在0.06美元到0.36美元之間<ref>{{cite web|title=Methotrexate Sodium|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=510&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=23 August 2016|archive-url=https://web.archive.org/web/20190611150720/http://mshpriceguide.org/en/single-drug-information/?DMFId=510&searchYear=2014|archive-date=2019-06-11|dead-url=yes}}</ref>。在美國，一個月的氨甲蝶呤治療費用大約為25美元至50美元
<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=464}}</ref>。

==醫學用途==
本药是目前最重要的控制抗[[類風濕性關節炎|類風濕性關節炎]] (rheumatoid arthritis，RA)的藥物之一，属于{{Link-en|疾病緩解抗風濕藥物|Disease-modifying antirheumatic drug}}(DMARDs)，其药理为減輕部份[[白血球|白血球]]（抗體）的炎症活動，進一步阻慢[[骨骼|骨骼]]的損害。

本藥僅可由對於抗代謝療法具有知識及經驗之醫師使用。高劑量治療惡性疾病曾有死亡之報告。
[[File:_Methotrexate_labelled_diagram.jpg|left]]
[[File:_Nci-vol-1831-300_Methotrexate.jpg|left]] 

==参考文献==
{{reflist}}
==外部連結==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/methotrexate | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Methotrexate | access-date = 2021-06-07 | archive-date = 2021-12-10 | archive-url = https://web.archive.org/web/20211210115436/https://druginfo.nlm.nih.gov/drugportal/name/methotrexate | dead-url = no }}
* [https://www.nras.org.uk/methotrexate-in-rheumatoid-arthritis National Rheumatoid Arthritis Society (NRAS)] {{Wayback|url=https://www.nras.org.uk/methotrexate-in-rheumatoid-arthritis |date=20191230212917 }} article on Methotrexate
* [https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682018.html Methotrexate Injection] {{Wayback|url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682018.html |date=20160705111354 }} MedlinePlus article from NIH

{{化疗药物}}
[[category:二氢叶酸还原酶抑制剂|category:二氢叶酸还原酶抑制剂]]
[[Category:免疫抑制剂|Category:免疫抑制剂]]
[[Category:抗肿瘤抗代谢物|Category:抗肿瘤抗代谢物]]
[[Category:抗叶酸物|Category:抗叶酸物]]
[[Category:苯甲酰胺|Category:苯甲酰胺]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:IARC第3类致癌物质|Category:IARC第3类致癌物质]]
[[Category:疾病調節抗風濕藥物|Category:疾病調節抗風濕藥物]]
[[Category:風濕病學|Category:風濕病學]]
[[Category:化學治療|Category:化學治療]]
[[Category:肝毒素|Category:肝毒素]]